Order: 1000ml D5W at 120ml/hr. Available: Macro drop 15ml/hr. What is the drip factor in drops per minute?

Choice A rationale

The half-life of a drug refers to the time it takes for the plasma concentration of a drug to reduce by half. It is not a primary consideration when substituting generic drugs for brand-name drugs.

Choice B rationale

Critical concentration is the amount of a drug needed to achieve therapeutic effects. While important, it is not the main factor in generic substitution.

Choice C rationale

Distribution describes how a drug is dispersed throughout the body's tissues and fluids. This factor is crucial for drug efficacy but not directly related to substituting generic drugs.

Choice D rationale

Bioavailability is the degree and rate at which an active drug ingredient is absorbed and becomes available at the site of action. Generic drugs must have the same bioavailability as brand-name drugs to ensure they are just as effective.

Choice A rationale

Working with animals is typically done in preclinical trials before phase I studies in humans and is not part of phase III drug evaluation studies.

Choice B rationale

Conducting research to determine the effectiveness of the drug is part of phase II studies. Phase III studies focus more on confirming effectiveness, monitoring side effects, and comparing it to commonly used treatments.

Choice C rationale

Monitoring and observing patients closely for adverse effects is a key responsibility in phase III drug evaluation studies. These studies involve a larger patient population to gather comprehensive safety and efficacy data.

Choice D rationale

Choosing appropriate patients to be involved in the study is primarily the responsibility of researchers and clinicians during the earlier phases of drug development, such as phase I and phase II studies.